Twist Bioscience - TWST Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.

6 brokers have issued 1 year target prices for Twist Bioscience's shares. Their TWST share price forecasts range from $29.00 to $43.00. On average, they predict the company's stock price to reach $33.83 in the next twelve months. This suggests a possible upside of 113.9% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.

Twist Bioscience's stock was trading at $23.81 on January 1st, 2023. Since then, TWST stock has decreased by 33.6% and is now trading at $15.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our TWST earnings forecast.

Twist Bioscience Co. (NASDAQ:TWST) released its earnings results on Friday, February, 3rd. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.35. The firm had revenue of $54.20 million for the quarter, compared to analyst estimates of $54.47 million. Twist Bioscience had a negative net margin of 99.23% and a negative trailing twelve-month return on equity of 27.35%. The business's revenue was up 29.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.91) EPS.

ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), ARK Innovation ETF (ARKK), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR S&P Biotech ETF (XBI), Putnam BioRevolution ETF (SYNB) and WisdomTree BioRevolution Fund (WDNA).

Twist Bioscience issued an update on its FY 2023 earnings guidance on Monday, February, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $261.00 million-$269.00 million, compared to the consensus revenue estimate of $265.53 million.

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.83%), JPMorgan Chase & Co. (6.85%), Sumitomo Mitsui Trust Holdings Inc. (5.18%), Nikko Asset Management Americas Inc. (5.16%), William Blair Investment Management LLC (3.60%) and Voya Investment Management LLC (2.76%). Insiders that own company stock include Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends.

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TWST stock can currently be purchased for approximately $15.82.

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $899.53 million and generates $203.57 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

The company employs 652 workers across the globe.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.